Global Liposomal Irinotecan Market Size, Share, and Trends Analysis Report, By Indications (Pancreatic Cancer, Lungs Cancer, Colorectal Cancer, and Others), By Application (Hospitals, Clinics, and Cancer Research Institutes), Forecast (2022-2028)

The global liposomal irinotecan market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Liposomal irinotecan is used to treat cancer that has spread to other parts of the body. It is usually given in combination with other cancer medicines. The global market is growing due to the increasing prevalence of cancer patients globally. According to National Cancer Statistics 2020, an estimation of 1,806,590 new cases of cancer were diagnosed in the US alone and 606,520 people died from the disease. The source also states that cancer is considered the leading cause of death worldwide. According to the WHO, 19.3 million new cancer cases were registered and 9.9 million deaths were registered globally in 2020. Therefore, the increasing prevalence of cancer patients globally and the adoption of new advanced technologies for the treatment of this disease are driving the growth of the global liposomal irinotecan market.

Pancreatic cancer is the most common type of cancer highly prevalent globally. According to the survey by the American Society of Clinical Oncology in September 2021, an estimation of 60,430 adults was diagnosed with pancreatic cancer and 48,220 deaths were registered in the US alone. The source also states that pancreatic cancer is the eighth most common cancer in women and the tenth most common cancer in men. Incidence rates of pancreatic cancer have gone up by around 1% each year since 2000.

Additionally, huge investment in research and development by the key manufacturer for the development to treat cancer disease as well as improved healthcare infrastructure in the emerging economic countries is driving the growth of the global liposomal irinotecan market. For instance, in November 2020, Ipsen Pharma received FDA approval for irinotecan liposome injection ONIVYDE as a second-line monotherapy treatment for small cell lung cancer. Similarly, according to an article by the Multidisciplinary Digital Publishing Institute published in February 2019, Liposomal Irinotecan will be used for the treatment of colorectal cancer in a preclinical model.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Indications
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pacira Pharmaceuticals, Inc., Eurofarma, and Ipsen Pharma,among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Liposomal Irinotecan Market Report by Segment

By Indications

• Pancreatic Cancer
• Lungs Cancer
• Colorectal Cancer
• Others

By Application

• Hospitals
• Clinics
• Cancer Research Institutes

Global Liposomal Irinotecan Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa